Senores Pharmaceuticals will acquire 100% of Apnar Pharma in a two-phase deal valued at ₹91 crore, assuming ₹76 crore in debt and paying ₹15 crore in cash, with completion expected by Q2 FY27. The acquisition adds a US FDA, UK MHRA, and Health Canada–approved facility near Vadodara and five approved ANDAs (15 strengths), including three ready for launch, addressing a US$722 million market.